TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Erica Mayer, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stamford Hospital
Stamford, Connecticut, United States
- Eastern Maine Medical Center (northern Light)
Brewer, Maine, United States
- New England Cancer Specialists
Scarborough, Maine, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Boston Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute at Steward St. Elizabeth'S
Brighton, Massachusetts, United States
- Dana-Farber Cancer Institute at Foxborough
Foxborough, Massachusetts, United States
- Dana-Farber Cancer Institute at Merrimack Valley
Methuen, Massachusetts, United States
- Dana-Farber Cancer Institute at Milford
Milford, Massachusetts, United States
- Dana-Farber Cancer Institute at South Shore
South Weymouth, Massachusetts, United States
- Dana-Farber Cancer Insitute at Londonderry Hospital
Londonderry, New Hampshire, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Oct 2023
- Primary completion
- 22 Jan 2025
- Completion
- 1 Jan 2027
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 90
- Registry id
- NCT06001762
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.